Therapeutic potential of Na(V)1.1 activators

Trends Pharmacol Sci. 2014 Mar;35(3):113-8. doi: 10.1016/j.tips.2013.12.007. Epub 2014 Jan 16.

Abstract

Sodium channel inhibitors have been developed and approved as drugs to treat a variety of indications. By contrast, sodium channel activators have not previously been considered relevant in a therapeutic setting owing to their high risk of toxicity and side effects. Here we present an opinion that selective activators of the Na(V)1.1 sodium channel may hold therapeutic potential for diseases such as epilepsy, schizophrenia, and Alzheimer's disease. Central to this novel avenue of sodium channel drug discovery is that fact that Na(V)1.1 comprises the majority of the sodium current in specific inhibitory interneurons. Conversely, it plays only a modest role in excitatory neurons owing to the high redundancy of other types of sodium channels in these cells. We discuss the biological background and rationale and present reflections on how to identify activators of Na(V)1.1.

Keywords: SCN1A mutations; cognition; connectivity; epilepsy; interneurons; oscillations; schizophrenia.

MeSH terms

  • Animals
  • Humans
  • Molecular Targeted Therapy
  • NAV1.1 Voltage-Gated Sodium Channel / metabolism*
  • Voltage-Gated Sodium Channel Blockers / pharmacology*
  • Voltage-Gated Sodium Channel Blockers / therapeutic use*

Substances

  • NAV1.1 Voltage-Gated Sodium Channel
  • Voltage-Gated Sodium Channel Blockers